Immunodermatology News

Men, along with clinicians with more than 4 years’ experience, were more likely than women and less experienced providers to prescribe oral small molecule medications and biologic immune response modifiers, according to a study.

Bimekizumab for the treatment of moderate to severe hidradenitis suppurativa met the primary endpoint and key secondary endpoint in two phase 3 studies, UCB announced in a press release.

Following an ED visit for hidradenitis suppurativa treatment, patients had a low rate of dermatology outpatient follow-up and a high rate of return ED visits for HS treatment within 180 days, according to a study.

Diagnosis of discoid lupus erythematosus in patients aged younger than 25 years may predict the onset of severe systemic lupus erythematosus, according to study findings.

Response-adapted therapy in melanoma, which involves removal of certain immunotherapeutic agents in a combination, can reduce costs without a decrease in efficacy, according to a study.

Proton pump inhibitors may be associated with pharmacovigilance signals for the occurrence of drug-induced lupus erythematosus, according to a research letter published in JAMA Dermatology.

Ruxolitinib cream 1.5% was associated with a significant improvement compared with vehicle in two trials of patients with vitiligo, according to a study.

Earlier this year, a group of researchers published data from long-term extension study of tofacitinib in patients with dermatomyositis, demonstrating a “sustained response” to a pan-JAK inhibitor in this population.

Almirall has announced the initiation of a phase 1 study evaluating ALM27134 for the treatment of autoimmune dermatological diseases, according to a company press release.

MILAN — Deucravacitinib demonstrated efficacy and safety in treating patients with systemic lupus erythematosus and sustained improvement up to 48 weeks.